| 1 | 2540587 | Lack of effectiveness of D-penicillamine in experimental arsenic poisoning. | Vet Hum Toxicol | 1989 Feb |
1 |
| 2 | 5847391 | [Supplement to a 1st plea on behalf of arsenous anhydride. Is the condemnation of arsenic unjust?]. | Actual Odontostomatol (Paris) | 1965 Sep |
1 |
| 3 | 6129183 | [Relationship between arsenic-induced hypothermia and brain monoamines. (2). The roles of noradrenaline and dopamine]. | Nihon Yakurigaku Zasshi | 1982 Aug |
1 |
| 4 | 6719100 | The speciation of the chemical forms of arsenic in the biological monitoring of exposure to inorganic arsenic. | Sci Total Environ | 1984 Mar 15 |
1 |
| 5 | 7747285 | Lung toxicity of hard metal particles and production of interleukin-1, tumor necrosis factor-alpha, fibronectin, and cystatin-c by lung phagocytes. | Toxicol Appl Pharmacol | 1995 May |
3 |
| 6 | 8704214 | In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. | Blood | 1996 Aug 1 |
12 |
| 7 | 8986606 | The PML and PML/RARalpha domains: from autoimmunity to molecular oncology and from retinoic acid to arsenic. | Exp Cell Res | 1996 Dec 15 |
1 |
| 8 | 9129041 | Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. | Blood | 1997 May 1 |
1 |
| 9 | 9129042 | Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. | Blood | 1997 May 1 |
4 |
| 10 | 9395660 | Characterization of differing effects caused by homeopathically prepared and conventional dilutions using cytochrome P450 2E1 and other enzymes as detection systems. | J Altern Complement Med | 1996 Summer |
1 |
| 11 | 9427741 | Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. | EMBO J | 1998 Jan 2 |
3 |
| 12 | 9450572 | Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. | J Natl Cancer Inst | 1998 Jan 21 |
2 |
| 13 | 9535176 | Acute promyelocytic leukemia: cellular and molecular basis of differentiation and apoptosis. | Pharmacol Ther | 1997 Oct-Dec |
4 |
| 14 | 9596679 | Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. | Blood | 1998 Jun 1 |
8 |
| 15 | 9716575 | Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. | Blood | 1998 Sep 1 |
14 |
| 16 | 9737686 | The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. | Leukemia | 1998 Sep |
2 |
| 17 | 9772451 | [Double effects of arsenic trioxide (As2O3) on acute promyelocytic leukemic cell line]. | Zhonghua Yi Xue Za Zhi | 1997 Jul |
6 |
| 18 | 9801394 | Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. | N Engl J Med | 1998 Nov 5 |
4 |
| 19 | 9834237 | Trivalent antimonials induce degradation of the PML-RAR oncoprotein and reorganization of the promyelocytic leukemia nuclear bodies in acute promyelocytic leukemia NB4 cells. | Blood | 1998 Dec 1 |
5 |
| 20 | 10023688 | Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient. | Oncogene | 1999 Jan 28 |
1 |
| 21 | 10190895 | Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. | J Exp Med | 1999 Apr 5 |
1 |
| 22 | 10328107 | Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. | J Natl Cancer Inst | 1999 May 5 |
2 |
| 23 | 10373566 | PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. | Mol Cell Biol | 1999 Jul |
12 |
| 24 | 10382944 | Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases. | Med Oncol | 1999 Apr |
2 |
| 25 | 10400422 | Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents. | Leukemia | 1999 Jul |
5 |
| 26 | 10428472 | Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. | FEBS Lett | 1999 Jul 16 |
2 |
| 27 | 10448126 | Low levels of arsenic trioxide stimulate proliferative signals in primary vascular cells without activating stress effector pathways. | Toxicol Appl Pharmacol | 1999 Aug 15 |
3 |
| 28 | 10477740 | Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. | Blood | 1999 Sep 15 |
2 |
| 29 | 10558879 | Effect of arsenic trioxide on cell cycle arrest in head and neck cancer cell line PCI-1. | Biochem Biophys Res Commun | 1999 Nov 19 |
3 |
| 30 | 10581825 | Efficacy of a potentized homoeopathic drug (Arsenicum Album-30) in reducing genotoxic effects produced by arsenic trioxide in mice: II. Comparative efficacy of an antibiotic, actinomycin D alone and in combination with either of two microdoses. | Complement Ther Med | 1999 Sep |
4 |
| 31 | 10615238 | Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. | Eur J Cancer | 1999 Aug |
1 |
| 32 | 10639594 | The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells. | Int J Mol Med | 2000 Feb |
1 |
| 33 | 10648417 | Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). | Blood | 2000 Feb 1 |
1 |
| 34 | 10673743 | Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. | Leukemia | 2000 Feb |
1 |
| 35 | 10674975 | In vitro exposure of acute promyelocytic leukemia cells to arsenic trioxide (As2O3) induces the solitary expression of CD66c (NCA-50/90), a member of the CEA family. | Tissue Antigens | 1999 Dec |
7 |
| 36 | 10712780 | [Antitumor effect of arsenic trioxide on mice experimental liver cancer]. | Zhonghua Gan Zang Bing Za Zhi | 2000 Feb |
2 |
| 37 | 10721769 | Arsenic-induced apoptosis in malignant cells in vitro. | Leuk Lymphoma | 2000 Mar |
2 |
| 38 | 10811458 | The effects of arsenic trioxide (As2O3) on human megakaryocytic leukemia cell lines. With a comparison of its effects on other cell lineages. | Leuk Lymphoma | 2000 Jun |
3 |
| 39 | 10830735 | Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy. | Leuk Lymphoma | 2000 Jul |
3 |
| 40 | 10841286 | As2O3 induces apoptosis of the human B lymphoma cell line MBC-1. | J Biol Regul Homeost Agents | 2000 Apr-Jun |
6 |
| 41 | 10850458 | Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. | Cancer Res | 2000 Jun 1 |
11 |
| 42 | 10910048 | BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity. | Cancer Res | 2000 Jul 1 |
12 |
| 43 | 10942401 | Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. | Blood | 2000 Aug 15 |
1 |
| 44 | 10954752 | Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. | Proc Natl Acad Sci U S A | 2000 Aug 29 |
8 |
| 45 | 11021749 | Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis. | Leukemia | 2000 Oct |
7 |
| 46 | 11068345 | Efficacy of a potentized homeopathic drug (Arsenicum-Aalbum-30) in reducing cytotoxic effects produced by arsenic trioxide in mice: IV. Pathological changes, protein profiles, and content of DNA and RNA. | Complement Ther Med | 2000 Sep |
1 |
| 47 | 11133770 | Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. | Blood | 2001 Jan 1 |
4 |
| 48 | 11135700 | [An experimental study on arsenic trioxide-selectively induced human hepatocarcinoma cell lines apoptosis and its related genes]. | Zhonghua Gan Zang Bing Za Zhi | 2000 Dec |
2 |
| 49 | 11146441 | Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3. | Int J Cancer | 2001 Jan 15 |
2 |
| 50 | 11150309 | Opposite effect of NF-kappa B and c-Jun N-terminal kinase on p53-independent GADD45 induction by arsenite. | J Biol Chem | 2001 Apr 6 |
19 |